Xortx outlines anticipated Health Canada clinical trial application for XRX-026 for gout
XRTX•Xortx outlined an anticipated Health Canada clinical trial application for XRX-026 for gout, said it has received increased inquiries from potential commercialization partners, and expects the first part of its XRX-OXY-102 study in Canada to accelerate an FDA NDA filing.
1. Application plans
Xortx said its application outlines a plan to advance XRX-026 toward regulatory approval in Canada and an NDA filing with the FDA. The company said the first part of its XRX-OXY-102 study in Canada is expected to accelerate the FDA filing.
